Though price cut cards might help ease the burden of substantial drug expenditures in the short term, they do not address the systemic concerns driving up prescription selling prices while in the U.S. Broader plan adjustments could deal with the foundation will cause of increasing drug costs, including lack of transparency in pricing plus the part